|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染显示文摘我非常高兴向大家推荐这份发展中国家幽门螺杆菌(H.priori)临床指南。该指南的编译是由数位在该领域具有丰富临床经验的世界知名专家共同完成的。 | Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F Van der Merwe S vaz Coelho LG Fock KM Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BC Krabshuis JH 杜颖 丛衍群 戴宁 | 2007 | 胃肠病学2007，12，1： | 85 |
| 2 | 世界胃肠病学组织全球指南——发展中国家幽门螺杆菌感染显示文摘世界上有一半人口感染幽门螺杆菌(H.pylori),其感染率因地理位置、种族、年龄和社会经济状况不同而存在很大差异.在发展中国家较高.发达国家较低。但总体而言,近年世界许多地区的H.pylori感染率均呈下降趋势。 | Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F van der Merwe S Vaz Coelho LG Fock M Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BCY Krabshuis J Le Mair A 杜颖 戴宁 | 2011 | 胃肠病学2011，16，7： | 27 |
| 3 | Gastric cancer, Helicobacter pylori infection and other risk factors显示文摘Gastric cancer incidence is declining. However, it is too early to consider this neoplastic disease as rare and the worldwide mortality rate still remains high. Several risk factors have been identif ied for non-cardia gastric cancer and primary prevention is feasible since most of the risk factors can be removed. Helicobacter pylori eradication treatment reduces but does not abolish gastric cancer risk. Indeed, gastric cancer is a multifactorial disease and removing one factor does not therefore prevent all cases. Endoscopic surveillance is still needed, especially in subjects at higher risk. The def inition of high-risk patients will be the future challenge as well as identifying the best surveillance strategy for such patients. | Lorenzo Fuccio Leonardo Henry Eusebi Franco Bazzoli | 2010 | World Journal of Gastrointestinal Oncology2010，2，9： | 17 |
| 4 | 幽门螺杆菌感染处理的当前观念——MaastrichtⅢ共识报告显示文摘名词缩写欧洲幽门螺杆菌研究小组:European Helicobacter Study Group,EHSG胃食管反流病:gastro-esophageal reflux disease。 | P Malfertheiner F Megraud C O'Morain F Bazzoli E El-Omar D Graham R Hunt T Rokkas N Vakil EJ Kuipers 朱琦 | 2007 | 胃肠病学2007，12，3： | 15 |
| 5 | Diagnosis and management of gastric antral vascular ectasia显示文摘Gastric antral vascular ectasia (GAVE) is an uncommon but often severe cause of upper gastrointestinal (GI) bleeding, responsible of about 4% of non-variceal upper GI haemorrhage. The diagnosis is mainly based on endoscopic pattern and, for uncertain cases, on histology. GAVE is characterized by a pathognomonic endoscopic pattern, mainly represented by red spots either organized in stripes radially departing from pylorus, defined as watermelon stomach, or arranged in a diffused-way, the so called honeycomb stomach. The histological pattern, although not pathognomonic, is characterized by four alterations:vascular ectasia of mucosal capillaries, focal thrombosis, spindle cell proliferation and fibrohyalinosis, which consist of homogeneous substance around the ectatic capillaries of the lamina propria. The main differential diagnosis is with Portal Hypertensive Gastropathy, that can frequently co-exists, since about 30% of patients with GAVE co-present a liver cirrhosis. Autoimmune disorders, mainly represented by Reynaud's phenomenon and sclerodactyly, are co-present in about 60% of patients with GAVE; other autoimmune and connective tissue disorders are occasionally reported such as Sjogren's syndrome, systemic lupus erythematosus, primary biliary cirrhosis and systemic sclerosis. In the remaining cases, GAVE syndrome has been described in patients with chronic renal failure, bone marrow transplantation and cardiac diseases. The pathogenesis of GAVE is still obscure and many hypotheses have been proposed such as mechanical stress, humoural and autoimmune factors and hemodynamic alterations. In the last two decades, many therapeutic options have been proposed including surgical, endoscopic and medical choices. Medical therapy has not clearly shown satisfactory results and surgery should only be considered for refractory severe cases, since this approach has significant mortality and morbidity risks, especially in the setting of portal hypertension and liver cirrhosis. Endoscopic therapy, particularly treatment with Argon Plasma Coagulation, has shown to be as effective and also safer than surgery, and should be considered the first-line treatment for patients with GAVE-related bleeding. | Lorenzo Fuccio Alessandro Mussetto Liboria Laterza Leonardo Henry Eusebi Franco Bazzoli | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，1： | 8 |
| 6 | The role of K- ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies显示文摘 | Lorenzo Fuccio Cesare Hassan Liboria Laterza Loredana Correale Nico Pagano Paolo Bocus Carlo Fabbri Antonella Maimone Vincenzo Cennamo Alessandro Repici Guido Costamagna Franco Bazzoli Alberto Larghi | 2013 | Gastrointestinal Endoscopy2013，，： | 4 |
| 7 | Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials显示文摘 | V. Cennamo L. Fuccio R. Zagari L. Eusebi L. Ceroni L. Laterza C. Fabbri F. Bazzoli | 2010 | Endoscopy2010，，05： | 3 |
| 8 | Pelvic radiation disease:Updates on treatment options显示文摘Pelvic cancers are among the most frequently diagnosed neoplasms and radiotherapy represents one of the main treatment options. The irradiation field usually encompasses healthy intestinal tissue,especially of distal large bowel,thus inducing gastrointestinal(GI) radiation-induced toxicity. Indeed,up to half of radiationtreated patients say that their quality of life is affected by GI symptoms(e.g.,rectal bleeding,diarrhoea). The constellation of GI symptoms- from transient to longterm,from mild to very severe- experienced by patients who underwent radiation treatment for a pelvic tumor have been comprised in the definition of pelvic radiation disease(PRD). A correct and evidence-based therapeutic approach of patients experiencing GI radiation-induced toxicity is mandatory. Therapeutic non-surgical strategies for PRD can be summarized in two broad categories,i.e.,medical and endoscopic. Of note,most of the studies have investigated the management of radiation-induced rectal bleeding. Patients with clinically significant bleeding(i.e.,causing chronic anemia) should firstly be considered for medical management(i.e.,sucralfate enemas,metronidazole and hyperbaric oxygen); in case of failure,endoscopic treatment should be implemented. This latter should be considered the first choice in case of acute,transfusion requiring,bleeding. More well-performed,high quality studies should be performed,especially the role of medical treatments should be better investigated as well as the comparative studies between endoscopic and hyperbaric oxygen treatments. | Leonardo Frazzoni Marina La Marca Alessandra Guido Alessio Giuseppe Morganti Franco Bazzoli Lorenzo Fuccio | 2015 | World Journal of Clinical Oncology2015，6，6： | 3 |
| 9 | Colorectal stenting as a bridge to surgery reduces morbidity and mortality in left-sided malignant obstruction: a predictive risk score-based comparative study显示文摘 | Vincenzo Cennamo Carmelo Luigiano Gianpiero Manes Rocco Maurizio Zagari Luca Ansaloni Carlo Fabbri Liza Ceroni Fausto Catena Antonio Daniele Pinna Lorenzo Fuccio Alessandro Mussetto Tino Casetti Federico Coccolini Nicola D’Imperio Franco Bazzoli | 2012 | Digestive and Liver Disease2012，，6： | 2 |
| 10 | Is more better? An analysis of hospital outcomes and efficiency with a DEA model of output con- gestion 显示文摘 | Clement J Valdmanis V Bazzoli G Zhao M Chukmaitov A | 2008 | Health Care Management Science2008，11，： | 1 |
| 11 | Epidemiology of Helicobacterpylori Infection显示文摘 | Eusebi LH Zagari RM Bazzoli F | 2014 | Helicobacter2014，191，： | 1 |
| 12 | Epidemiology of Helicobacter pylori Infection显示文摘 | Leonardo H. Eusebi Rocco M. Zagari Franco Bazzoli | 2014 | Helicobacter2014，，： | 1 |
| 13 | reriew article:Should NSAID /low-dose aspiyin takers be tested yout inely for H pylori infection and treated if positive Infection for primary,risk of ulcer and ulcer relaps afer inilial lvealing显示文摘 | Hunt RH Bazzoli F | 2004 | Aliment Pharmacol Ther2004，19，： | 1 |
| 14 | Incidence and recurrence rates of colorectal adenomas in first - degree asymptomatic relatives of patients with colon cancer 显示文摘 | Fossi S Bazzoli F Ricciardiello L | | Am J Gastroenterol0，96，： | 1 |
| 15 | PCNA and apoptosis during post-spawning ovarian remodeling in the teleost Oreochromis niloticus显示文摘 | Rafael M.C. Melo Yuri S. Martins Ronald K. Luz Elizete Rizzo Nilo Bazzoli | 2015 | Tissue and Cell2015，，： | 1 |
| 16 | Helicobacter pylori erad-ication with a capsule containing bismuth subcitrate potassium, met-ronidazole ,and tetracycline given with omeprazole versus clarithromy-cin-based triple therapy : a randomised,open-label,non-inferiority,phase 3 trial显示文摘 | Malfertheiner P Bazzoli F Delchier JC | 2011 | Lancet2011，377，9769： | 1 |
| 17 | Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials显示文摘 | V. Cennamo L. Fuccio R. Zagari L. Eusebi L. Ceroni L. Laterza C. Fabbri F. Bazzoli | 2010 | Endoscopy2010，，05： | 1 |
| 18 | Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial显示文摘 | Peter Malfertheiner Franco Bazzoli Jean-Charles Delchier Krysztof Celi?ski Monique Giguère Marc Rivière Francis Mégraud | 2011 | The Lancet2011，，9769： | 1 |
| 19 | Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium,metronidazole,and tetracycline given with omeprazole vemus clarithromycin-based triple therapy:a randomised,open-label,non-inferiority,phase 3trial显示文摘 | Malfertheiner P Bazzoli F Delchier JC | | 0，，9769： | 1 |
| 20 | Timing of precut procedure does not influence success rate and complications of ERCP procedure: a prospective randomized comparative study显示文摘 | Vincenzo Cennamo Lorenzo Fuccio Alessandro Repici Carlo Fabbri Diego Grilli Massimo Conio Nicola D’Imperio Franco Bazzoli | 2009 | Gastrointestinal Endoscopy2009，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员